We are live on ! Find out more
ARCT icon

Arcturus Therapeutics

136 hedge funds and large institutions have $477M invested in Arcturus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more call options, than puts

Call options by funds: $41.6M | Put options by funds: $21M

42% more capital invested

Capital invested by funds: $336M → $477M (+$140M)

23% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 40

0.21% more ownership

Funds ownership: 95.01%95.22% (+0.21%)

5% less funds holding

Funds holding: 143136 (-7)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

Holders
136
Holders Change
-7
Holders Change %
-4.9%
% of All Funds
1.78%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
49
Reduced
40
Closed
28
Calls
$41.6M
Puts
$21M
Net Calls
+$20.6M
Net Calls Change
+$17.4M

ARCT Hedge Fund Activity: Q3 2025 in Review

136 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2025, worth a combined $477M — up 42% from $336M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of ARCT and 22 opened new positions — a net loss of 6 holders — while 40 trimmed existing stakes and 49 added.

The largest buyer was Arrowstreet Capital, adding an estimated $8.27M. The largest seller was Woodline Partners, cutting an estimated $11.5M.

  • 136 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2025, down from 143 in Q2 2025.
  • Funds reported $477M of Arcturus Therapeutics stock for Q3 2025, up 42% quarter-over-quarter.
  • 22 funds opened new Arcturus Therapeutics positions in Q3 2025 and 28 closed out, a net change of -6 holders.
  • The largest Arcturus Therapeutics buyer in Q3 2025 was Arrowstreet Capital, an estimated $8.27M added.
  • The largest Arcturus Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $11.5M sold.

Based on aggregated 13F filings for Q3 2025.